High-Purity Research Compounds | Trusted Quality & Consistency
High-Purity Research Compounds | Trusted Quality & Consistency
£279.00
Retatrutide is nicknamed “Triple G” because it is a single molecule that activates three different nutrient-stimulated hormone receptors:
GLP-1 (Glucagon-like peptide-1): Promotes satiety, slows digestion, and reduces overall calorie intake.
GIP (Glucose-dependent insulinotropic polypeptide): Improves insulin sensitivity and facilitates more efficient fat metabolism.
GCG (Glucagon Receptor): Increases energy expenditure (metabolic rate) and specifically helps reduce fat accumulated in the liver.
By targeting all three pathways simultaneously, Retatrutide has demonstrated superior weight loss results in early trials compared to “dual agonists” like Tirzepatide (Mounjaro) or “single agonists” like Semaglutide (Wegovy).
(Triple-action peptide)
Retatrutide (also known as LY3437943) is a potent, experimental “triple agonist” peptide being developed primarily for the treatment of obesity, type 2 diabetes, and metabolic-associated fatty liver disease (MASH).
CAS Number: 2381089-83-2
Molecular Formula: 3$C_{221}H_{342}N_{46}O_{68}$
Molecular Weight: Approximately 4731.42 g/mol4
Appearance: Typically a white lyophilized (freeze-dried) powder or a clear solution if pre-filled in a pen.
In the context of research and supply, a 40mg specification usually refers to a multi-dose vial or pen. It is important to note:
Not a Single Dose: In Phase 2 and Phase 3 clinical trials, the highest weekly dose administered to participants was 12mg.
Usage: A 40mg product is designed to provide multiple weekly injections (for example, four doses of 10mg each) through a single delivery device or vial.
Reconstitution: If in powder form, it requires sterile bacteriostatic water for reconstitution before subcutaneous injection.
Clinical Trials: Retatrutide is currently in Phase 3 clinical trials (the TRIUMPH series).
Efficacy: Research indicates the potential for an average weight loss of up to 24% over 48 weeks.
Administration: It is administered via a once-weekly subcutaneous injection in the abdomen, thigh, or upper arm.
[!CAUTION] Retatrutide is still an investigational drug and is not yet FDA-approved for general medical use. High-concentration formats like 40mg are primarily used in clinical research settings or by specialized suppliers.
